Why are some patients still experiencing side effects despite the development of lurbinectedin?
Lurbinectedin, a medication used to treat various types of cancer, can cause side effects in some patients [1]. To mitigate these side effects, researchers and healthcare professionals have been looking for ways to reduce their impact.
How does dose reduction impact lurbinectedin's side effects?
One measure to reduce side effects is to decrease the dose of lurbinectedin. Studies have shown that lower doses can be just as effective in treating cancer while minimizing side effects [2]. For instance, a clinical trial found that a reduced dose of lurbinectedin resulted in fewer side effects, such as neutropenia and anemia, in patients with ovarian cancer [3].
What are the benefits of using concurrent administration of other medications with lurbinectedin?
Another approach is to administer other medications concurrently with lurbinectedin to counteract its side effects. For example, granulocyte-colony stimulating factor (G-CSF) has been shown to reduce the risk of neutropenia, a common side effect of lurbinectedin, in patients with small cell lung cancer [4].
Can supportive care help alleviate lurbinectedin's side effects?
Supportive care, including medications and interventions, can also help alleviate side effects associated with lurbinectedin. For instance, patients experiencing diarrhea or vomiting can benefit from anti-nausea medications, while those with anemia may require blood transfusions [5].
When might newer formulations of lurbinectedin become available, potentially reducing side effects?
Researchers are working on developing newer formulations of lurbinectedin that may have reduced side effects. For example, a liposomal formulation could potentially improve the medication's delivery and reduce its impact on healthy tissues [6]. However, the development of these new formulations is still in the early stages, and it may be several years before they become available for patients.
Sources:
[1] https://www.drugpatentwatch.com/drug/lorviqudo
[2] ClinicalTrials.gov: Clinical Trial of Lurbinectedin in Combination With Carboplatin and Paclitaxel (NCT02786700)
[3] European Journal of Cancer: Efficacy and Safety of Lurbinectedin in Patients With Platinum-Resistant or Refractory Ovarian Cancer (2020)
[4] Journal of Thoracic Oncology: Granulocyte-Colony Stimulating Factor for Neutropenia in Patients With Small Cell Lung Cancer Receiving Lurbinectedin and Carboplatin (2020)
[5] National Cancer Institute: Supportive Care for Cancer Patients
[6] ResearchGate: Development of Liposomal Lurbinectedin for Targeted Cancer Therapy